WR1 (ASX) WR1 General Discussion

Originally posted by dynofish: ↑

Hi Siva

Comparisons?

WR1 is about where LTR was just before LTR's offtake agreements. Decent MRE and coming off a period of weak pricing for Spodumene.
Offtake agreements can deliver a lot by way of confidence to shareholders and prospective shareholders. I recall that when LTR announced its offtakes, there was a sense of euphoria among shareholders that we had a project that others wanted to be in on. The terms of the offtakes generally were kept confidential, but the Ford one delivered a massive fillip by way of the $300m loan on attractive terms.
LTR was at a point in the EV revolution that was way less certain than today. So I would say WR1 is even more on the cusp of greatness than LTR was.
Both have great management. I think the major shareholding of TIm Goyder in LTR, was a big plus, but the compensation and perhaps even greater advantage of WR1 is its extremely tight register and very low shares on issue. Use of FTF has been extremely well exploited by WR1.
Both have tier 1 jurisdiction but WR1 has some climatic challenges that LTR did not have, but none of those are extreme.
Both have resources that are easily accessed with low strip ratios to ore. Scale wise, LTR does have a bigger resources, but WR1 is still exploring with lots of scope to grow its resource..
The greatest difference now is the access to a very cheap and quick to deliver operating plant! This is a true ace up the sleeve of WR1 and marks us up as a premium investment opportunity for anyone in the lithium space.
That also means time to market could be a massive advantage over global competing start ups. The future is always uncertain, so if WR1 can cut maybe 2 years from its commencement of production, then shareholders are sitting pretty.
Canada is way less developed as a supply hub, and the government there is arguably ahead on support. Offsetting this is both the permitting issues which are slower (WR1 has the solution to this with Renard), and the lack of infrastructure in our part of Quebec. If the road can be resolved then this is solved too.
Both companies have credible ESG credentials and good relationships and policies with indigenous cultures.
There are many similarities, but knowing what I now know about the market etc. I think I am even more satisfied to hold a decent chunk of WR1 as I have been with LTR. Better risk/reward imo for its stage of development.

I could write a lot more but I think it's summed up okay at a high level. Even the two hotcopper forums have a depth of knowledge and quality posters as each other. I have been mostly an observer on WR1 and it's a quality forum imo. I feel fortunate to be a shareholder. : )

Regards
DF

Expand

The similarities are indeed remarkable even down to the two forums consisting of religious zealots who refuse to allow any commentary other than blind optimism and delusion for the stock that is held. Emotion takes over every discussion.

You don’t need to look much further than the crew of posters who somehow decided that $3+ (on market) was somehow ‘underpriced’ lol

No.	Vol.	Price($)
1	873	68.5¢

No.

Vol.

Price($)

873

68.5¢

Price($)	Vol.	No.
69.0¢	10000	1

Price($)

Vol.

No.

69.0¢

10000

No.	Vol.	Price($)
1	873	0.685
2	3538	0.680
2	38097	0.675
8	92126	0.670
4	28150	0.665

No.

Vol.

Price($)

873

0.685

3538

0.680

38097

0.675

92126

0.670

28150

0.665

Price($)	Vol.	No.
0.690	10000	1
0.700	10314	2
0.705	35000	2
0.710	11630	3
0.715	22500	1

Price($)

Vol.

No.

0.690

10000

0.700

10314

0.705

35000

0.710

11630

0.715

22500

(20min delay)
Last 68.5¢		Change -0.015(2.14%)		Mkt cap ! $148.1M

Open	High	Low	Value	Volume
70.0¢	70.5¢	67.5¢	$464.9K	676.4K

WR1 General Discussion, page-27905

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

WR1 General Discussion, page-27905

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News